TNX-4200

Preclinical

Phase I

Phase II

Phase III

TNX-4200
Preclinical
Anti-CD40 ligand mAb

Preclinical

Host-directed antiviral discovery program

  • CD45 targeted therapeutics
    • Small molecule therapeutics that reduce endogenous activity of CD45, a protein tyrosine phosphatase
    • Reduction in CD45 protects against many viruses including the Ebola virus
BACK TO PIPELINE